Project Grant W81XWH2110886

This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $4,000,000.00 in funding to Medcura, Inc. in Riverdale, MD to expand the development and production of a biopolymer powder treatment for noncompressible torso hemorrhage. The research aims to improve health outcomes for military service members and the broader public by advancing this innovative medical technology. The award period extends from Aug 5,...

This Project Grant award of $2,461,670.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of ErythroMer (EM), a dried, bio-inspired artificial red blood cell substitute, by Kalocyte Inc., a biotech startup. The project aims to optimize the lyophilization and reconstitution of EM to improve its oxygen binding and release properties, as well as evaluate its efficacy, pharmacokinetics, dosing, and compatibility with...

The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, awarded a $1,249,317 Project Grant to Sanaheal Inc. for the development and validation of a "Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding." The objective is to optimize and validate this hemostatic paste to meet FDA regulatory requirements in preparation for a future pivotal clinical trial and commercialization....

This $516,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program will support the development of injectable cellulose-based hydrogels for soft tissue bulking from July 1, 2022 to June 30, 2024. The Research Foundation of the City University of New York, in partnership with the City University of New York, will engineer a stable yet reversible injectable soft tissue filler material derived from plant polysaccharides like cellulose. If successful,...

The Texas A&M Engineering Experiment Station (Tees) was awarded a $2,404,778 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research and development of expandable hemostats for treatment of noncompressible intracaivitary hemorrhage from August 15, 2022 to August 14, 2026. Through this funding, Tees will investigate medical solutions for uncontrolled bleeding on the battlefield,...

Emergency Medical Innovation LLC received a $256,000 Project Grant award from the National Science Foundation to develop a nasal compression device with medicated intranasal sponges for treating nosebleeds. Funded through the NSF's Engineering program (CFDA 47.041), the award will support design and testing of a nasal clip capable of consistently applying proper pressure levels and eluting appropriate doses of medication for nosebleed treatment when placed nominally. Over the one-year period...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $507,517 to the University of Washington to develop novel, synthetic therapies for stabilizing trauma victims in the critical "golden hour" after injury. The key objectives are to engineer low volume resuscitants that provide fluid resuscitation...

The U.S. Defense Health Agency awarded a $1,996,885 project grant under the Military Medical Research and Development program (CFDA 12.420) to Selsym Biotech Inc., a woman-owned small business. The funding supports the development of SYMCLOT, a synthetic platelet mimetic particle technology, to augment hemostasis for patients requiring extracorporeal support, such as those with battlefield injuries. Previous grants from the National Institutes of Health have also supported Selsym Biotech's...

The U.S. Department of Defense (DoD) Defense Health Agency awarded a $1,820,004 Project Grant to Case Western Reserve University's Office of Research Administration Division, doing business as the University Hospitals of Cleveland, under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," will support the development of an innovative nanoparticle-based technology...

Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...